MRSA
20
2
2
11
Key Insights
Highlights
Success Rate
85% trial completion
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 29/100
10.0%
2 terminated out of 20 trials
84.6%
-1.9% vs benchmark
45%
9 trials in Phase 3/4
45%
5 of 11 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 11 completed trials
Clinical Trials (20)
Vancomycin Dosing for Serious MRSA Infections: A Non-inferiority Randomized Trial of Trough Level Versus AUC/MIC
Evaluation of the Decolonization Rate and Acceptance of a Complete Nasal Decolonization Kit With Povidone Iodine for MRSA Patients
Optimal Treatment of MRSA Throat Carriers
Antibiotic Prophylaxis in High-Risk Arthroplasty Patients
MRSA Decolonization in Complicated Carriage
MRSA Eradication and Decolonization in Children
Vancomycin Monitoring: Is AUC Monitoring Appropriate for More Than Just Serious MRSA Infections?
AeroVanc in the Treatment of Methicillin-resistant Staphylococcus Aureus Infection in Patients With Cystic Fibrosis
Epidemiology and Treatment of Small-colony Variant Staphylococcus Aureus in Cystic Fibrosis
Community-Assoc. S. Aureus Colonization and Recurrent Infection in Pts With Uncomplicated S. Aureus Skin Abscesses
Retapamulin as a Decolonizing Agent for MRSA
Tracing MRSA in Households With Patients Infected With CA-MRSA by WGS
Use of Disposable Stethoscope Covers for Reduction of Stethoscope MRSA Contamination
Surveillance of Community-Associated MRSA
Benefits of Universal Glove and Gowning
Comparison of Standard Isolation With Targeted Isolation for Preventing Nosocomial Transmission of MRSA and VRE
Stop Community MRSA Colonization Among Patients
Effect of Weight and/or Obesity on Sulfamethoxazole and Trimethoprim Concentrations
Pharmacokinetics/ Pharmacodynamics (PK/PD) Study of Vancomycin
The Underlying Mechanisms For S. Aureus Infection And Colonization Of Skin in People With Atopic Dermatitis With And Without Eczema Herpeticum (MRSA)